Drug research

Venetoclax

Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.

Drug identity checked against registry records

Also recorded as Venclexta; Venclexta®; Venclyxto

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

Trial	Sponsor	Phase	Status	Primary completion
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2NCT04229979	Sellas Life Sciences Group	Phase 3	Active not recruiting	2025-12Estimated
Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or VenetoclaxNCT04016805	TGTX	Phase 2	Terminated	2022-05-22Actual
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLNCT07007312	KURA	Phase 3	Recruiting	2031-11Estimated
Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)NCT03801525	TGTX	Phase 2, Phase 3	Terminated	2022-12-20Actual

Sellas Life Sciences GroupActive not recruitingPrimary completion: 2025-12 · Estimated

Trial details

TGTXTerminatedPrimary completion: 2022-05-22 · Actual

Trial details

KURARecruitingPrimary completion: 2031-11 · Estimated

Trial details

TGTXTerminatedPrimary completion: 2022-12-20 · Actual

Trial details

No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed.